Drug Profile
Emerfetamab - BeiGene
Alternative Names: AMG 673; Anti-CD33xanti-CD3-BiTE; Anti-CD33xanti-CD3-BiTE-bispecific-T-cell-engagerLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; BeiGene
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Acute myeloid leukaemia
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in China (IV, Infusion)
- 20 Dec 2021 Amgen terminates a phase-I trial in Acute myeloid leukaemia (Second-line therapy or greater) in Germany, Australia and USA (IV) (NCT03224819)
- 09 Feb 2021 Suspended - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in Australia (IV)